just endure…

Posted on Tuesday 2 July 2013

for every roach you see, there are a hundred behind the wall…

One thing about transparency, it’s irrelevant if you don’t look. So first, Propublica’s Dollars for Docs:

Charles B. Nemeroff   Johnson & Johnson   2011   Meals   $111
Charles Barnet Nemeroff Allergan 2012 Combination $1-1,000
Charles Nemeroff Eli Lilly 2011 Meals $118
Charles Nemeroff
(Payee: SCIENTIFIC THERAPEUTICS INFORM)
GlaxoSmithKline 2011 Consulting $2,098

Remember Scientific Therapeutics Information? That’s where ghost-writer Sally Laden used to work [Paxil Study 329, Paxil Study 352, the Nemeroff and Schatzberg Recognition and Treatment of Psychiatric Disorders, and so much more]. But that’s not all. The University of Miami has their own disclosure database:

Charles B. Nemeroff MD PhD
Outside Professional Activities
The University of Miami Health System (UHealth) and the Miller School of Medicine
    [Type of Activity]   Compensation

2010 Aclimed [Other] $1,000 or less
2010 American Institute of Biological Sciences [Grant Review] $1,000 or less
2010 American Institute of Biological Sciences [Other] $1,000 or less
2010 American Psychiatric Institute for Research and Education [Teaching] $1,000 or less
2010 American Psychiatric Publishing, Inc. [Royalties] $10,001 – $25,000
2010 Authors Registry [Royalties] $1,000 or less
2010 BioStrategies [Other] $1,000 or less
2010 CeNeRx BioPharma [Other] $1,000 or less
2010 CeNeRx BioPharma [Scientific Advisory Board] $5,001 – $10,000
2010 Commerce Analyst [Other] $1,000 or less
2010 Ellsevier [Royalties] $1,000 or less
2010 Florida Psychiatric Society [Lecture] $1,000 or less
2010 Harvard University (Lecture) $1,000 – $5,000
2010 John Wiley & Sons (Royalties) $1,000 or less
2010 John Wiley & Sons, Inc. (Royalties) $1,000 or less
2010 MedSurvey (Other) $1,000 or less
2010 Mount Cook Pharma (Board of Directors) $0
2010 NovaDel Pharma, Inc. (Board of Directors) $10,001 – $25,000
2010 Ohio State University (Lecture) $1,000 – $5,000
2010 Orlando Health/Third International Brain Conference (Lecture) $1,000 or less
2010 PharmaNeuroBoost (Scientific Advisory Board) $1,000 – $5,000
2010 Quantia Communications Inc. (Other) $1,000 or less
2010 Revaax Pharma (Other) $0
2010 Schochor, Federico and Staton, P.A. (Expert Witness) $1,000 – $5,000
2010 Springer [Royalties] $1,000 or less
2010 Tufts University [Lecture] $1,000 – $5,000
2010 University of British Columbia, Vancouver [Lecture] $1,000 – $5,000
2010 University of Illinois [Lecture] $1,000 – $5,000
2011 American Institute of Biological Sciences [Grant Review] $1,000 – $5,000
2011 American Physician Institute for Advanced Professional Studies [Lecture] $5,001 – $10,000
2011 American Psychiatric Association [Royalties] $10,001 – $25,000
2011 American Psychiatric Publishing [Royalties] $10,001 – $25,000
2011 Associacion de Psiquiatras Region Bayamon [Lecture] $1,000 – $5,000
2011 Beth Israel Deaconess Medical Center [Lecture] $1,000 – $5,000
2011 CHUBB Group of Insurance Companies [Great Northern Insurance Company] [Expert Witness] $1,000 – $5,000
2011 CME Outfitters [Lecture] $10,001 – $25,000
2011 CeNeRx Biopharma [Other] $1,000 – $5,000
2011 CeNeRx Biopharma [Scientific Advisory Board] $25,001 – $50,000
2011 Comsort [Other] $1,000 or less
2011 Continuing Education Wizards [Lecture] $1,000 – $5,000
2011 Edward Health Services Corporation [Expert Witness] $1,000 – $5,000
2011 Elsevier [Other] $1,000 – $5,000
2011 Florida Psychoanalytic Society [Lecture] $1,000 or less
2011 George West Mental Health Foundation/Skyland Trail [Board of Directors] $1,000 – $5,000
2011 Georgia Psychiatric Physicians Association [Lecture] $1,000 – $5,000
2011 Great Northern Insurance Company [Expert Witness] $1,000 or less
2011 Harvard University [Lecture] $1,000 – $5,000
2011 International Conference on Schizophrenia Research [Lecture] $1,000 or less
2011 John Wiley & Sons, Inc. [Royalties] $1,000 – $5,000
2011 Kenes MP Asia [Lecture] $5,001 – $10,000
2011 Les Laboratoires Servier [Other] $1,000 – $5,000
2011 North American Center for Continuing Medical Education [Other] $10,001 – $25,000
2011 NovaDel Pharma [Board of Directors] $50,001 – $100,000
2011 NovaDel Pharma [Other] $1,000 or less
2011 Oxford University Press [Other] $1,000 – $5,000
2011 PharmaNeuroBoost [Scientific Advisory Board] $50,001 – $100,000
2011 Roche [Consulting] $1,000 – $5,000
2011 SK Life Science [Consulting] $5,001 – $10,000
2011 SS Chicago, LLC [Other] $1,000 or less
2011 Schochor, Federico & Staton P.A. [Expert Witness] $1,000 – $5,000
2011 Sotolongo PA [Expert Witness] $1,000 – $5,000
2011 Springer Publishing Company [Other] $1,000 or less
2011 Takeda [Consulting] $5,001 – $10,000
2011 Takeda Pharmaceuticals [Consulting] $5,001 – $10,000
2011 The Authors Registry [Royalties] $1,000 or less
2011 The Ohio State University [Lecture] $5,001 – $10,000
2011 USF Health Professions Conferencing Corporation [Lecture] $1,000 – $5,000
2011 University of Florida [Lecture] $1,000 or less
2011 University of South Florida [Consulting] $1,000 – $5,000
2011 University of Wisconsin [Lecture] $1,000 – $5,000
2011 XIII Simposio Internacional de Psiquiatria [Lecture] $1,000 – $5,000
2011 Xhale [Consulting] $10,001 – $25,000

Please note the 2011 period covers an 18 month window. This was intentional to allow transition
from the UM fiscal year to the calendar year. Beginning in 2012, the reporting period will align with
the calendar year.

For 2011 [18 months] that puts him between $226,000 and $560,000 [that shows]. In an ever changing world, some things just endure…
  1.  
    July 2, 2013 | 6:21 PM
     

    Spectacular. Isn’t the silence by the majority of our colleagues just amazing?

    If I ever wrote a book about the state of psychiatry, I have had the title for over 15 years now, “Whores and Cowards: how the Hippocratic Oath transformed into the Hypocritical Oath”. But, not written yet, because there is no target audience.

    Oh, my mistake, there is a “target” audience, except my interest is not to target the audience, but to educate and enlighten them. My colleagues as a whole just walk around with dual scope lens for glasses, because they are targeting their audience, who to take out next for the sake of a buck.

    Ironic, the patients seen as “bucks” to make bucks.

    By the way, after my day today, psychotherapy by in large is dead as a viable concept for a treatment intervention. Witnessed it’s epitaph at a meeting!

    I’ll write about it tonight or tomorrow at my site. Cheers!

  2.  
    Nancy Wilson
    July 2, 2013 | 7:10 PM
     

    Thanks for the tip, Mickey.

    According to the disclosure database for UT Southwestern faculty, AstraZeneca paid Madhukar Trivedi fees in the range to $5,000 to $9,999 in 2013. See Mickey’s post “seroquel, good to the last drop…”

    Today I left a voicemail message for Angela Wishon, Vice President for Research Administration, UT Southwestern Medical Center, regarding the university’s investigation into Dr. Trivedi’s outside employment activities. I will add this to my list of questions.

  3.  
    CannotSay2013
    July 2, 2013 | 8:02 PM
     

    Truly amazing. This Nemeroff guy is like CEOs at corporate America. He cashes in regardless of the magnitude of his incompetence and corruption. The real question is how is that the guy is not yet in jail.

  4.  
    Tom
    July 2, 2013 | 8:33 PM
     

    I need some money. I am calling Charlie for a loan.

  5.  
    wiley
    July 3, 2013 | 2:06 PM
     

    All this money for peddling is vulgar. He cheapens education and experience by taking so many bribes while representing himself as a “leader” in an academic field.

  6.  
    July 3, 2013 | 4:52 PM
     

    Vulgar, nah, it is criminal, because he lets profit motives shape clinical opinion, and really has no remorse if/when the consequences play out the alleged treatment interventions were incorrect.

    Note phrase “has no remorse”. Why there is too much antisocial crap in medicine that is either minimized, deflected, or pathologically denied.

    Happy 4th.

  7.  
    jamzo
    July 4, 2013 | 10:13 AM
     

    fyi

    http://economix.blogs.nytimes.com/2013/07/02/most-u-s-health-spending-is-exploding-but-not-for-mental-health/

    “direct mental health spending has remained roughly 1 percent of the economy since 1986, while total health spending climbed from about 10 percent of gross domestic product in 1986 to nearly 17 percent in 2009. ”

    “For most medical conditions, costs per person have gone up, but for mental disorders and heart conditions, they have fallen slightly.

    So what is holding costs down?”

  8.  
    jamzo
    July 4, 2013 | 10:17 AM
     

    LINK TO MAGAZINE ARTICLE REFERRED TO ABOVE

    It’s the Economy
    The Half-Trillion-Dollar Depression
    By CATHERINE RAMPELL
    Published: July 2, 2013 24 Comments

    http://www.nytimes.com/2013/07/02/magazine/the-half-trillion-dollar-depression.html?partner=rss&emc=rss&pagewanted=all&_r=0

  9.  
    Johanna
    July 6, 2013 | 1:22 PM
     

    Thanks for this Jamzo! My theory: the runup in the price of meds has been amazing as has the number of people put on them and the number of meds per person. However, it’s all been accompanied by a radical reduction in inpatient and outpatient psych services which cancels out the jump in pharma expenses. Mainly thanks to the insurance industry. Insurance and PhARMA like to quarrel in public as it makes both of them look better to us patients. In reality they are bosom buddies.

    Thirty years ago psych meds were handled gingerly enough that people were often taken into the hospital for two weeks “to adjust their meds.” Now it is impossible to get hospitalized unless you have threatened to kill yourself or hurt someone else. (Granted, hospitalization was never a bed of roses but the current emergency-only system has greatly enhanced its dehumanizing and coercive character. ) And good luck finding an MD shrink who is even prepared to take your blood pressure! They will tell you to see your family doctor for that. As for outpatient, counselors tell me that these days you get twelve weeks, then the insurance co asks if the patient is on meds? If not, they tell you they must not be ill enough to need therapy.

Sorry, the comment form is closed at this time.